AstraZeneca PLC (AZN) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis...

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

First and only next-generation oral SERD and complete ER antagonist to demonstrate 1st-line benefit in combination with widely approved CDK4/6...

Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN

Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights...

AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN

AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action...

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial

IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone Results from a post-hoc...

AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights - AZN

AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before...

Investors who lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action - AZN

Investors who lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class Action...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]